Advanced biomaterials for cancer theranostic
Keywords:
cancer, immunotherapy, Nano biomaterials, nanoparticles, liposomes, micelles, hydrogel, micro needles, dendritic cells (DCs)Abstract
Immunotherapy, as a strong system for malignant growth treatment, has accomplished huge viability in clinical preliminaries. Notwithstanding these headways, there is a lot of towards do as far as improving remedial advantages and diminishing results of disease immunotherapy. Progressed nano biomaterials, including liposomes, polymers, and silica, assume a fundamental part in code livery of medications also, immune modulators. These nano biomaterial-based conveyance frameworks could successfully advance antitumor invulnerable reactions what's more, all while diminish harmful unfavorable impacts. Besides, Nano biomaterials may likewise consolidate with one another or with conventional medications through various components, along these lines leading towards more precise and productive cancer therapy. Here, an outline of most recent headway in these Nano biomaterials utilized for malignant growth immunotherapy is given, portraying extraordinary frameworks, counting lipid-based nanoparticles, polymer-based platforms or micelles, inorganic nano systems, and others.
Downloads
References
Quesada JR, Hersh EM, Manning J, Reuben J, Keating M, Schnipper E, et al. Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood. 1986;68:493–7.
Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18:175–96.
Mandal A, Boopathy AV, Lam LKW, Moynihan KD, Welch ME, Bennett NR, et al. Cell and fluid sampling microneedle patches for monitoring skin-resident immunity. SciTransl Med. 2018;10:eaar2227.
Dellacherie MO, Seo BR, Mooney DJ. Macroscale biomaterials strategies for local immunomodulation. Nat Rev Mater. 2019;4:379–97.
Wang C, Ye Y, Hu Q, Bellotti A, Gu Z. Tailoring biomaterials for cancer immunotherapy: emerging trends and future outlook. Adv Mater. 2017;29:29.
Coley WB.treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. ClinOrthopRelat Res. 1991;262:3–11.
Storni T, Kundig TM, Senti G, Johansen P. Immunity in responsetowardsparticulate antigen-delivery systems. Adv Drug Deliv Rev. 2005;57:333–55.
De Koker S, Lambrecht BN, Willart MA, van Kooyk Y, Grooten J, Vervaet C, et al. Designing polymeric particles for antigen delivery. ChemSoc Rev. 2011;40:320–39.
Silva JM, Videira M, Gaspar R, Preat V, Florindo HF. Immune system targeting by biodegradable nanoparticles for cancer vaccines. J Control Release. 2013;168:179–99.
Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. 2002;2:251–62.
GilboaE.promise of cancer vaccines. Nat Rev Cancer. 2004;4:401–11.
Ahmed S, Rai KR. Interferon intreatment of hairy-cell leukemia. Best Pr Res ClinHaematol. 2003;16:69–81.
Rosenberg SA. IL-2:first effective immunotherapy for human cancer. J Immunol. 2014;192:5451–8
Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers. 2011;3:3856–93.
Alwan LM, Grossmann K, Sageser D, Van Atta J, Agarwal N, Gilreath JA. Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma. Target Oncol. 2014;9:63–71
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, et al. A progress report ontreatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889–97
Tanimoto T, Hori A, Kami M. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:1966–8.
Graff JN, Chamberlain ED. Sipuleucel-T intreatment of prostate cancer: an evidence-based review of its place in therapy. Core Evid. 2015;10:1–10.
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
